City Therapeutics closed at $21.15 on Nov 2, up 2.12%, 5.6% below its highest close since Oct 16. Volume of 180.3K shares was 0.49× its 20-day average (below normal).
Short interest was 21.3K shares at the Nov 30 settlement, down 65.5% from the prior report (0.0% of float, 1.0 days to cover).
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
What is CTY's market cap?
$1.06B, based on the Nov 2 close of $21.15.
How much of CTY is sold short?
21.3K shares, 0.0% of float, as of Nov 30, 2020.
About City Therapeutics
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology